Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Haploidentical HSCT–going from strength to strength
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Dr. Joseph Rosenthal
https://cell-source.com/wp-content/uploads/2020/12/copy-of-joseph-rosenthal.jpg
300
300
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Dr. Joseph RosenthalScientific Advisory Board Member Director of Pediatric Hematology - Oncology and Chair in Pediatrics at City of Hope National Medical Center Earning an MD from Tel-Aviv University, Dr.…
read more
Towards Safer Allogeneic HSCT in Autoimmunity: Proof-of-concept in Diabetes-Prone Mice
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Murine anti-third-party central memory CD8 T cells promote hematopoietic chimerism under mild conditioning; lymph-node sequestration and deletion of anti-donor T cells
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Location, location, location: advancing veto cell therapies
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Towards ‘off-the-shelf’ genetically modified T cells; prolonging functional engraftment in mice by CD8 veto T cells
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Proof of Concept for Repair of Sickle Cell Disease By Non-Myeloablative MHC Disparate T Cell Depleted HSCT Combined with Donor-Derived Veto Cells
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Next Generation Veto T cells Directed Against Memory Antigens
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png
Immunotherapy is an Idea
https://cell-source.com/wp-content/themes/movedo/images/empty/thumbnail.jpg
150
150
Cell Source, Inc.
//cell-source.com/wp-content/uploads/2021/10/clcs-logo-2021-negative-glow.png